Veltassapatiromer
According to the FDA label: Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] . Veltassa is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
13,710 adverse event reports submitted to the FDA (2016–2026)
Top Reported Adverse Events
The most frequently reported events in association with Veltassa in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Constipation 2,141 reports
Difficulty passing stool, or having fewer bowel movements than usual.
Full definition in the glossary → See all drugs reporting this event →Death 1,811 reports
A report that the person died. A death appearing in reports for a drug does not mean the drug caused it. Reports record that a death occurred while the medication was being used, which can happen for many unrelated reasons.
Full definition in the glossary →Diarrhoea 1,292 reports
Loose or watery bowel movements, often frequent. Also spelled diarrhea in American English.
Full definition in the glossary → See all drugs reporting this event →Hospitalisation 970 reports
A report that the person was admitted to a hospital. This records that a hospital stay occurred, which is one way the seriousness of an event is tracked. Also spelled hospitalization in American English.
Full definition in the glossary →Off Label Use 927 reports
Using a medication for a condition or in a way that the FDA has not officially approved. This is common and often legal, and a report of it does not mean something went wrong. Doctors sometimes prescribe drugs off label based on their judgment.
Full definition in the glossary →- Blood Potassium Increased 795 reports
Nausea 709 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →Drug Dose Omission 672 reports
A report that a dose of medication was missed or skipped.
Full definition in the glossary →Malaise 581 reports
A general feeling of being unwell or uncomfortable, without a specific symptom.
Full definition in the glossary →Abdominal Discomfort 540 reports
A general unease or mild pain in the belly area.
Full definition in the glossary →Inappropriate Schedule of Drug Administration 461 reports
A report that a medication was taken on the wrong schedule, such as too often or at the wrong time. This is a usage category, the same idea as inappropriate schedule of product administration.
Full definition in the glossary →Vomiting 446 reports
Throwing up the contents of the stomach.
Full definition in the glossary → See all drugs reporting this event →Abdominal Pain Upper 426 reports
Pain in the upper part of the belly, above the navel.
Full definition in the glossary →No Adverse Event 377 reports
A report that was filed but did not actually describe any adverse event. This is a record-keeping category.
Full definition in the glossary →Dyspnoea 371 reports
Shortness of breath or difficulty breathing. Also spelled dyspnea in American English.
Full definition in the glossary → See all drugs reporting this event →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Male | 7,612 |
| Female | 5,732 |
| Unknown | 16 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 16 |
| 18-34 | 100 |
| 35-49 | 495 |
| 50-64 | 1,729 |
| 65-74 | 2,185 |
| 75+ | 2,657 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Veltassa. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 7,028 |
| Hospitalization | 3,766 |
| Death | 2,102 |
| Other Serious | 1,699 |
| Life-Threatening | 55 |
| Disability | 14 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Veltassa. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2016 | 3,462 |
| 2017 | 4,594 |
| 2018 | 1,774 |
| 2019 | 1,327 |
| 2020 | 896 |
| 2021 | 569 |
| 2022 | 313 |
| 2023 | 192 |
| 2024 | 191 |
| 2025 | 317 |
| 2026 (partial) | 75 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Veltassa
In FDA adverse event reports that mention Veltassa, these medications appeared most often in the same report.
- Furosemide (2,036 reports)
- Carvedilol (1,523 reports)
- Ergocalciferol (1,523 reports)
- Metoprolol (1,348 reports)
- Atorvastatin (1,271 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026